Modelling A.I. in Economics

Rapid Recovery for Rapid Micro (RPID)?

Outlook: RPID Rapid Micro Biosystems Inc. Class A is assigned short-term B2 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Ensemble Learning (ML)
Hypothesis Testing : Wilcoxon Sign-Rank Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

This exclusive content is only available to premium users.


This exclusive content is only available to premium users.
This exclusive content is only available to premium users.

ML Model Testing

F(Wilcoxon Sign-Rank Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Ensemble Learning (ML))3,4,5 X S(n):→ 1 Year i = 1 n a i

n:Time series to forecast

p:Price signals of RPID stock

j:Nash equilibria (Neural Network)

k:Dominated move of RPID stock holders

a:Best response for RPID target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

RPID Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Rapid Micro Biosystems: Unveiling the Future of Financial Success

Rapid Micro Biosystems, a leading provider of automated microbial detection and enumeration systems, has demonstrated remarkable growth and resilience in the face of market challenges. The company's financial trajectory has been characterized by consistent revenue increases, strategic acquisitions, and a commitment to innovation. Analysts predict that Rapid Micro Biosystems will continue to flourish in the coming years, driven by its robust product portfolio, expanding customer base, and focus on quality and compliance.

Rapid Micro Biosystems' financial performance has been on a steady upward trend. In the past fiscal year, the company reported a substantial increase in revenue, driven by strong demand for its Growth Direct System and the successful integration of recent acquisitions. This revenue growth is expected to persist in the coming years as the company expands its market reach and introduces new products and services. The company's solid financial position provides a strong foundation for future investments and growth initiatives.

One of Rapid Micro Biosystems' key strengths lies in its innovative product portfolio. The company's Growth Direct System has gained widespread recognition for its ability to deliver rapid and accurate microbial detection and enumeration, helping manufacturers ensure product quality and safety. Additionally, Rapid Micro Biosystems has a robust pipeline of new products and technologies in development, which are expected to further enhance its competitive position and drive revenue growth.

Rapid Micro Biosystems' commitment to quality and compliance has been a cornerstone of its success. The company's products and processes adhere to stringent regulatory standards, making them a preferred choice for manufacturers in highly regulated industries. This focus on quality and compliance is expected to continue to be a key differentiator for the company, contributing to its long-term success and customer loyalty.

Rating Short-Term Long-Term Senior
Income StatementBaa2B3
Balance SheetCBa3
Leverage RatiosCCaa2
Cash FlowB1Caa2
Rates of Return and ProfitabilityBa1Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?This exclusive content is only available to premium users.This exclusive content is only available to premium users.This exclusive content is only available to premium users.

Rapid Micro Biosystems' Path Amidst Market Volatility

Since its inception in 2005, Rapid Micro Biosystems (RMB) has steadily carved a niche in the microbiology testing industry. Its innovative Growth Direct System, a rapid microbial detection platform, has been widely adopted across pharmaceutical, personal care, and food and beverage industries. However, the company's journey on the stock market has been far from smooth, with its share price experiencing significant fluctuations over the years.

The company's stock performance has been influenced by a multitude of factors, including shifts in market sentiment, competition from established players, and the overall economic landscape. Despite these challenges, Rapid Micro Biosystems has demonstrated resilience, consistently delivering positive revenue growth and expanding its product portfolio. However, investors should be cognizant of the associated risks before making investment decisions.

One notable risk is the company's dependence on a limited number of products. The Growth Direct System is the primary revenue generator for RMB, accounting for a substantial portion of its sales. While the system has proven to be successful, any potential issues or market shifts could adversely affect the company's financial performance. Additionally, the company's exposure to the healthcare industry makes it susceptible to changes in regulatory policies and reimbursement rates, which could impact demand for its products.

Despite these risks, Rapid Micro Biosystems' focus on innovation and its strong track record of revenue growth position it for continued success. The company's commitment to developing cutting-edge technologies and expanding its product offerings can mitigate some of the inherent risks associated with its business model. Long-term investors may find value in RMB's potential for sustained growth, but they should remain vigilant in monitoring the company's progress and the ever-changing market dynamics.


  1. Athey S, Imbens GW. 2017b. The state of applied econometrics: causality and policy evaluation. J. Econ. Perspect. 31:3–32
  2. Chipman HA, George EI, McCulloch RE. 2010. Bart: Bayesian additive regression trees. Ann. Appl. Stat. 4:266–98
  3. Zou H, Hastie T. 2005. Regularization and variable selection via the elastic net. J. R. Stat. Soc. B 67:301–20
  4. Kitagawa T, Tetenov A. 2015. Who should be treated? Empirical welfare maximization methods for treatment choice. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London
  5. R. Howard and J. Matheson. Risk sensitive Markov decision processes. Management Science, 18(7):356– 369, 1972
  6. Dudik M, Langford J, Li L. 2011. Doubly robust policy evaluation and learning. In Proceedings of the 28th International Conference on Machine Learning, pp. 1097–104. La Jolla, CA: Int. Mach. Learn. Soc.
  7. J. Filar, L. Kallenberg, and H. Lee. Variance-penalized Markov decision processes. Mathematics of Opera- tions Research, 14(1):147–161, 1989


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.